Sensus Healthcare (NASDAQ:SRTS) Releases Quarterly Earnings Results, Misses Expectations By $0.41 EPS

Sensus Healthcare (NASDAQ:SRTS) released its quarterly earnings data on Thursday. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41), FiscalAI reports. Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%. The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $4.60 million.

Sensus Healthcare Trading Up 1.0%

Sensus Healthcare stock traded up $0.03 during mid-day trading on Thursday, hitting $3.16. 57,669 shares of the company’s stock were exchanged, compared to its average volume of 65,921. Sensus Healthcare has a 1-year low of $2.66 and a 1-year high of $5.49. The stock has a 50 day moving average of $2.94 and a two-hundred day moving average of $3.67. The stock has a market cap of $52.01 million, a P/E ratio of -6.72 and a beta of 1.10.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SRTS. Wall Street Zen downgraded Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $6.75.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SRTS. XTX Topco Ltd bought a new position in shares of Sensus Healthcare in the 4th quarter valued at approximately $77,000. Rothschild Wealth LLC bought a new position in shares of Sensus Healthcare in the fourth quarter valued at approximately $500,000. Greenline Wealth Management LLC bought a new position in shares of Sensus Healthcare in the fourth quarter valued at approximately $513,000. Ingalls & Snyder LLC acquired a new stake in shares of Sensus Healthcare in the fourth quarter worth $219,000. Finally, State Street Corp boosted its holdings in shares of Sensus Healthcare by 5.2% during the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after buying an additional 3,400 shares during the period. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.